October 4, 2018
FDA: Endo Pharmaceuticals recalls two lots of Robaxin
Editor's Note
The Food & Drug Administration on September 28 announced the recall by Endo Pharmaceuticals Inc of two lots of Robaxin 750 mg tablets because of incorrect dosing information on the label.
Robaxin contains methocarbamol, which is used as a muscle relaxant. Patients who follow the incorrect dosing information may experience significant drowsiness and dizziness or they may have an overdose that results in seizures, coma, or death.
To date, the company has not received any reports of adverse events related to the recall.
Free Daily News
- Augmented reality gains FDA nod, 10k-case milestone in orthopedics, strides in outpatient surgery
- Smart patient selection anchors DISC’s high-acuity spine ASC model
- Postop opioid prescriptions following outpatient surgery see steep, sustained fall
- Study: Bariatric surgery offers cost, survival benefits for cirrhosis patients
- AI monitoring, remote surgery advance
- Rethinking OR routines reduces waste, costs while protecting environment
- Proposed Oregon legislation blocks AI tools from using 'nurse' title
- Communications skills keep surgical patients engaged, informed
- Study: Daytime meals protect heart health in night shift workers
- Borescope inspections reveal widespread contamination in lumened surgical instruments
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement